Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Bronchoscopy | Research

Repeated bronchoscopy in health and obstructive lung disease: is the airway microbiome stable?

Authors: Rune Nielsen, Yaxin Xue, Inge Jonassen, Ingvild Haaland, Øyvind Kommedal, Harald G. Wiker, Christine Drengenes, Per S. Bakke, Tomas M. L. Eagan

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Objective

Little is known concerning the stability of the lower airway microbiome. We have compared the microbiota identified by repeated bronchoscopy in healthy subjects and patients with ostructive lung diseaseases (OLD).

Methods

21 healthy controls and 41 patients with OLD completed two bronchoscopies. In addition to negative controls (NCS) and oral wash (OW) samples, we gathered protected bronchoalveolar lavage in two fractions (PBAL1 and PBAL2) and protected specimen brushes (PSB). After DNA extraction, we amplified the V3V4 region of the 16S rRNA gene, and performed paired-end sequencing (Illumina MiSeq). Initial bioinformatic processing was carried out in the QIIME-2 pipeline, identifying amplicon sequence variants (ASVs) with the DADA2 algorithm. Potentially contaminating ASVs were identified and removed using the decontam package in R and the sequenced NCS.

Results

A final table of 551 ASVs consisted of 19 × 106 sequences. Alpha diversity was lower in the second exam for OW samples, and borderline lower for PBAL1, with larger differences in subjects not having received intercurrent antibiotics. Permutational tests of beta diversity indicated that within-individual changes were significantly lower than between-individual changes. A non-parametric trend test showed that differences in composition between the two exams (beta diversity) were largest in the PSBs, and that these differences followed a pattern of PSB > PBAL2 > PBAL1 > OW. Time between procedures was not associated with increased diversity.

Conclusion

The airways microbiota varied between examinations. However, there is compositional microbiota stability within a person, beyond that of chance, supporting the notion of a transient airways microbiota with a possibly more stable individual core microbiome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Drengenes C, Wiker H, Kalananthan T, Nordeide E, Eagan T, Nielsen R. Laboratory contamination in airway microbiome studies. BMC Microbiol. 2019;19(1):187.CrossRef Drengenes C, Wiker H, Kalananthan T, Nordeide E, Eagan T, Nielsen R. Laboratory contamination in airway microbiome studies. BMC Microbiol. 2019;19(1):187.CrossRef
2.
go back to reference Grønseth R, Drengenes C, Wiker H, Tangedal S, Xue Y, Husebø G, et al. Protected sampling is preferable in bronchoscopic studies of the airway microbiome. ERJ Open Res. 2017;3:00019–2017.CrossRef Grønseth R, Drengenes C, Wiker H, Tangedal S, Xue Y, Husebø G, et al. Protected sampling is preferable in bronchoscopic studies of the airway microbiome. ERJ Open Res. 2017;3:00019–2017.CrossRef
3.
go back to reference Salter S, Cox M, Turek E, Calus S, Cookson W, Moffatt M, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 2014;12:87.CrossRef Salter S, Cox M, Turek E, Calus S, Cookson W, Moffatt M, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 2014;12:87.CrossRef
4.
go back to reference Segal LN, Clemente JC, Wu BG, Wikoff WR, Gao Z, Li Y, et al. Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax. 2017;72(1):13–22.CrossRef Segal LN, Clemente JC, Wu BG, Wikoff WR, Gao Z, Li Y, et al. Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax. 2017;72(1):13–22.CrossRef
5.
go back to reference Twigg HL 3rd, Knox KS, Zhou J, Crothers KA, Nelson DE, Toh E, et al. Effect of advanced HIV infection on the respiratory microbiome. Am J Respir Crit Care Med. 2016;194(2):226–35.CrossRef Twigg HL 3rd, Knox KS, Zhou J, Crothers KA, Nelson DE, Toh E, et al. Effect of advanced HIV infection on the respiratory microbiome. Am J Respir Crit Care Med. 2016;194(2):226–35.CrossRef
6.
go back to reference Wang J, Lesko M, Badri MH, Kapoor BC, Wu BG, Li Y, et al. Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-gamma. ERJ Open Res. 2017;3:00008-2017.CrossRef Wang J, Lesko M, Badri MH, Kapoor BC, Wu BG, Li Y, et al. Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-gamma. ERJ Open Res. 2017;3:00008-2017.CrossRef
7.
go back to reference Mayhew D, Devos N, Lambert C, Brown J, Clarke S, Kim V, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73(5):422–30.CrossRef Mayhew D, Devos N, Lambert C, Brown J, Clarke S, Kim V, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73(5):422–30.CrossRef
8.
go back to reference Sinha R, Weissenburger-Moser L, Clarke J, Smith L, Heires A, Romberger D, et al. Short term dynamics of the sputum microbiome among COPD patients. PLoS ONE. 2018;13(3):e0191499.CrossRef Sinha R, Weissenburger-Moser L, Clarke J, Smith L, Heires A, Romberger D, et al. Short term dynamics of the sputum microbiome among COPD patients. PLoS ONE. 2018;13(3):e0191499.CrossRef
9.
go back to reference Grønseth R, Haaland I, Wiker H, Martinsen E, Leiten E, Husebø G, et al. The Bergen COPD microbiome study (MicroCOPD): rationale, design, and initial experiences. Eur Clin Respir J. 2014;1:26196.CrossRef Grønseth R, Haaland I, Wiker H, Martinsen E, Leiten E, Husebø G, et al. The Bergen COPD microbiome study (MicroCOPD): rationale, design, and initial experiences. Eur Clin Respir J. 2014;1:26196.CrossRef
10.
go back to reference Martinsen E, Eagan T, Leiten E, Nordeide E, Bakke P, Lehmann S, et al. Motivation and response rates in bronchoscopy studies. Multidiscip Respir Med. 2019;14:14.CrossRef Martinsen E, Eagan T, Leiten E, Nordeide E, Bakke P, Lehmann S, et al. Motivation and response rates in bronchoscopy studies. Multidiscip Respir Med. 2019;14:14.CrossRef
12.
go back to reference Bolyen E, Rideout J, Dillon M, Bokulich N, Abnet C, Al-Ghalith G, et al. QIIME 2: reproducible, interactive, scalable, and extensible microbiome data science. PeerJ Prepr. 2018;6:e27295v2. Bolyen E, Rideout J, Dillon M, Bokulich N, Abnet C, Al-Ghalith G, et al. QIIME 2: reproducible, interactive, scalable, and extensible microbiome data science. PeerJ Prepr. 2018;6:e27295v2.
13.
go back to reference Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4:e2584.CrossRef Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4:e2584.CrossRef
14.
go back to reference Navas-Molina J, Peralta-Sánchez J, González A, McMurdie P, Vázquez-Baeza Y, Xu Z, et al. Advancing our understanding of the human microbiome using QIIME. Methods Enzymol. 2013;531:371–444.CrossRef Navas-Molina J, Peralta-Sánchez J, González A, McMurdie P, Vázquez-Baeza Y, Xu Z, et al. Advancing our understanding of the human microbiome using QIIME. Methods Enzymol. 2013;531:371–444.CrossRef
15.
go back to reference Bokulich N, Kaehler B, Rideout J, Dillon M, Bolyen E, Knight R, et al. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2’s q2-feature-classifier plugin. Microbiome. 2018;6(1):90.CrossRef Bokulich N, Kaehler B, Rideout J, Dillon M, Bolyen E, Knight R, et al. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2’s q2-feature-classifier plugin. Microbiome. 2018;6(1):90.CrossRef
17.
go back to reference Paulson J, Stine O, Bravo H, Pop M. Differential abundance analysis for microbial marker-gene surveys. Nat Methods. 2013;10(12):1200–2.CrossRef Paulson J, Stine O, Bravo H, Pop M. Differential abundance analysis for microbial marker-gene surveys. Nat Methods. 2013;10(12):1200–2.CrossRef
18.
go back to reference Bassis C, Erb-Downward J, Dickson R, Freeman C, Schmidt T, Young V, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio. 2015;6(2):e00037.CrossRef Bassis C, Erb-Downward J, Dickson R, Freeman C, Schmidt T, Young V, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio. 2015;6(2):e00037.CrossRef
19.
go back to reference Tangedal S, Aanerud M, Grønseth R, Drengenes C, Wiker H, Bakke P, et al. Comparing microbiota profiles in induced and spontaneous sputum samples in COPD patients. Respir Res. 2017;18(1):164.CrossRef Tangedal S, Aanerud M, Grønseth R, Drengenes C, Wiker H, Bakke P, et al. Comparing microbiota profiles in induced and spontaneous sputum samples in COPD patients. Respir Res. 2017;18(1):164.CrossRef
20.
go back to reference Dickson R, Erb-Downward J, Martinez F, Huffnagle G. The microbiome and the respiratory tract. Annu Rev Physiol. 2016;78:481–504.CrossRef Dickson R, Erb-Downward J, Martinez F, Huffnagle G. The microbiome and the respiratory tract. Annu Rev Physiol. 2016;78:481–504.CrossRef
21.
go back to reference Dickson R, Erb-Downward J, Freeman C, McCloskey L, Beck J, Huffnagle G, et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann Am Thorac Soc. 2015;12(6):821–30.CrossRef Dickson R, Erb-Downward J, Freeman C, McCloskey L, Beck J, Huffnagle G, et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann Am Thorac Soc. 2015;12(6):821–30.CrossRef
22.
go back to reference Durack J, Huang Y, Nariya S, Christian L, Ansel K, Beigelman A, et al. Bacterial biogeography of adult airways in atopic asthma. Microbiome. 2018;6(1):104.CrossRef Durack J, Huang Y, Nariya S, Christian L, Ansel K, Beigelman A, et al. Bacterial biogeography of adult airways in atopic asthma. Microbiome. 2018;6(1):104.CrossRef
23.
go back to reference Einarsson G, Comer D, McIlreavey L, Parkhill J, Ennis M, Tunney M, et al. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax. 2016;71:795–803.CrossRef Einarsson G, Comer D, McIlreavey L, Parkhill J, Ennis M, Tunney M, et al. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax. 2016;71:795–803.CrossRef
24.
go back to reference Erb-Downward J, Thompson D, Han M, Freeman C, McCloskey L, Schmidt L, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS ONE. 2011;6(2):e16384.CrossRef Erb-Downward J, Thompson D, Han M, Freeman C, McCloskey L, Schmidt L, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS ONE. 2011;6(2):e16384.CrossRef
25.
go back to reference Pragman A, Kim H, Reilly C, Wendt C, Isaacson R. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS ONE. 2012;7(10):e47305.CrossRef Pragman A, Kim H, Reilly C, Wendt C, Isaacson R. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS ONE. 2012;7(10):e47305.CrossRef
26.
go back to reference Morris A, Beck J, Schloss P, Campbell T, Crothers K, Curtis J, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med. 2013;187(10):1067–75.CrossRef Morris A, Beck J, Schloss P, Campbell T, Crothers K, Curtis J, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med. 2013;187(10):1067–75.CrossRef
Metadata
Title
Repeated bronchoscopy in health and obstructive lung disease: is the airway microbiome stable?
Authors
Rune Nielsen
Yaxin Xue
Inge Jonassen
Ingvild Haaland
Øyvind Kommedal
Harald G. Wiker
Christine Drengenes
Per S. Bakke
Tomas M. L. Eagan
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01687-0

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.